A new variant CYP2D6 allele (CYP2D6*21) with a single base insertion in exon 5 in a Japanese population associated with a poor metabolizer phenotype

被引:28
|
作者
Chida, M
Yokoi, T
Nemoto, N
Inaba, M
Kinoshita, M
Kamataki, T
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Lab Drug Metab, Div Pharmacobiodynam,Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Toxicol, Toyama, Japan
[3] Otsuka Pharmaceut Co Ltd, Tokushima 77101, Japan
[4] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
来源
PHARMACOGENETICS | 1999年 / 9卷 / 03期
关键词
CYP2D6*3; CYP2D6*4; CYP2D6*5; CYP2D6*18; genotype;
D O I
10.1097/00008571-199906000-00003
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Two poor metabolizer individuals of debrisoquine were identified among 215 healthy Japanese by a phenotyping test, Analysis of the CYP2D6 gene from one of two poor metabolizers, who was not homozygous for the previously described CYP2D6 Variant alleles (CYP2D6*3, CYP2D6*4, CYP2D6*5 and CYP2D6*18), showed that this individual was heterozygous for a new allele, CYP2D6/C8 (CYP2D6*21), CYP2D6*21 I had a single cytosine insertion at position 2661 in exon 5, This cytosine insertion generated a stop codon at the 17 bp downstream of this insertion site, A method to detect this allele was established with an allele specific-polymerase chain reaction, This method showed that another one of two poor metabolizers also possessed CYP2D6*21 allele heterozygously, In 318 healthy Japanese, five individuals carried this allele, heterozygously (0.81%, 5/636 chromosomes), Based on the present and our previous data, the poor metabolizer frequency in Japanese was estimated to be 0.39%, which accounted for approximately 45% of the individuals phenotyped as poor metabolizers by in-vivo tests. Pharmacogenetics 9:287-293 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:287 / 293
页数:7
相关论文
共 50 条
  • [31] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [32] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [33] Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele
    Manoharan, Aarthi
    Shewade, Deepak Gopal
    Ravindranath, Pradeep Anand
    Rajkumar, Ravi Philip
    Ramprasad, Vedam L.
    Adithan, Surendiran
    Damodaran, Solai Elango
    PHARMACOGENOMICS, 2019, 20 (10) : 719 - 730
  • [34] Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population
    Mitsunaga, Y
    Kubota, T
    Ishiguro, A
    Yamada, Y
    Sasaki, H
    Chiba, K
    Iga, T
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 505 (1-2) : 83 - 85
  • [35] A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics
    Blake, C. M.
    Kharasch, E. D.
    Schwab, M.
    Nagele, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (03) : 394 - 399
  • [36] CYP2D6 METABOLIZER PHENOTYPE PREDICTS ARIPIPRAZOLE PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS
    Hiken, Eliah J.
    Poweleit, Ethan A.
    Keane, Corey
    Desta, Zeruesenay
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2023, 62 (10): : S197 - S197
  • [37] Genotype and allele frequency of CYP2D6 in Tamilian population
    C. Adithan
    N. Gerard
    A. T. Naveen
    K. Koumaravelou
    C. H. Shashindran
    R. Krishnamoorthy
    European Journal of Clinical Pharmacology, 2003, 59 : 517 - 520
  • [38] Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation:: a study of mutations CYP2D6*3 and CYP2D6*4
    Monek, O
    Paintaud, G
    Bechtel, Y
    Miguet, JP
    Mantion, G
    Bechtel, PR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (01) : 47 - 52
  • [39] DETECTION OF THE POOR METABOLIZER-ASSOCIATED CYP2D6(D) GENE DELETION ALLELE BY LONG-PCR TECHNOLOGY
    STEEN, VM
    ANDREASSEN, OA
    DALY, AK
    TEFRE, T
    BORRESEN, AL
    IDLE, JR
    GULBRANDSEN, AK
    PHARMACOGENETICS, 1995, 5 (04): : 215 - 223
  • [40] Impact of CYP2D6 metabolizer phenotype on the safety profile of paliperidone ER
    Dunbar, Fiona
    Chue, Pierre
    Fu, Dong-Jing
    Huang, Qiqing
    Franc, Monique-Andree
    Cohen, Nadine
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 83S - 83S